Adam Weiner, Urologic Surgeon at Cedars-Sinai, shared a post on X:
“Testosterone replacement therapy after surgery for prostate cancer.
SPIRIT trial:
- RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men
- TRT started ≥2 yrs post-RP w/ undetectable PSA
- 12 wks testosterone vs placebo
- Increased sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak
- Zero biochemical recurrences
- Short-term, proof-of-concept.
- Bigger/longer trials including patients with higher-risk disease needed.”
Title: Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial
Authors: Shalender Bhasin, Arthur Burnett, Thiago Gagliano-Jucá, Thomas Storer, Kieran Reid, Yili Valentine Shang, Fabiola Privat, Mohan Chandra, Mary Weiss, Yusnie Memish-Beleva, Helen Lam, Adam Kibel, Karol Pencina
Other articles about Prostate Cancer on OncoDaily.
